Scarica l'app Stockscreener
10.27
4.95%
0.43
Corbus Pharmaceuticals Holdings Inc Borsa (CRBP) Ultime notizie
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
CRBP Q2 2026 Earnings: Wider-Than-Expected Loss of $1.81 Per Share, Yet Shares Advance 3.96%Earnings Yield Spread - Vinanet
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Corbus Pharmaceuticals (CRBP) Holds Near $10.09 as Traders Eye $10.59 ResistanceOption Breadth - Vinanet
Corbus Pharmaceuticals (CRBP) Holds Near $10 as Buyers Defend Key SupportCovered Call ETF - Vinanet
Corbus Pharmaceuticals (CRBP): Citadel entities and Kenneth Griffin disclose 1.1% stake - Stock Titan
Price-Driven Insight from (CRBP) for Rule-Based Strategy - Stock Traders Daily
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Mizuho lowers Corbus Pharmaceuticals stock price target on model updates - Investing.com
Mizuho lowers Corbus Pharmaceuticals stock price target on model updates By Investing.com - Investing.com Canada
CRBP Insider Buying: Chief Business Officer Nishant Saxena Purch - GuruFocus
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $33 - Moomoo
Corbus Pharmaceuticals (NASDAQ:CRBP) Insider Buys 2,600 Shares of Stock - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Corbus Chief Business Officer Nishant Saxena acquires 2,600 shares worth $25,037.44 - Bitget
Research Analysts Set Expectations for CRBP Q3 Earnings - MarketBeat
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals (NASDAQ:CRBP) CEO Yuval Cohen Sells 17,000 Shares of Stock - MarketBeat
Sean Moran Sells 12,000 Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) Stock - MarketBeat
Corbus Pharmaceuticals Holdings Inc Actuals & Estimates (NASDAQ:CRBP) - TradingView
Corbus Pharmaceuticals (NASDAQ:CRBP) Cut to "Strong Sell" at Wall Street Zen - MarketBeat
Corbus Pharmaceuticals Holdings Inc (CRBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Stock News Today - TradingKey
CRBP (NASDAQ: CRBP) insider plans 12,000-share sale via Stifel - Stock Titan
CRBP (CRBP) holder files to sell 17,000 Nasdaq-traded shares - Stock Titan
CRBP Maintained by Oppenheimer -- Price Target Lowered to $48.00 - GuruFocus
Oppenheimer Issues Pessimistic Forecast for Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price - MarketBeat
CRBP Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $48 From $52, Maintains Outperform Rating - marketscreener.com
H.C. Wainwright Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $35 - Moomoo
HC Wainwright Has Lowered Expectations for Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price - MarketBeat
William Blair Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating - Moomoo
Form 8K Corbus Pharmaceuticals Holding For: 6 August By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals (NASDAQ: CRBP) ramps R&D to $51M as cash backs key trials - Stock Titan
Corbus Pharmaceuticals Holdings, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update - The Manila Times
Corbus Pharmaceuticals (NASDAQ: CRBP) doubles Q2 loss while securing FDA clearance for Phase 3 trial - Stock Titan
Corbus Pharmaceuticals: Q2 Earnings Snapshot - marketscreener.com
Corbus Pharmaceuticals (CRBP) Holds Gains as Biotech Momentum BuildsLow Vol ETF - Vinanet
Corbus Pharmaceuticals Announces Last Patient Last Visit In Canyon-1 Study Of CRB-913 For The Treatment Of Obesity - marketscreener.com
Corbus Pharmaceuticals (CRBP) Completes Final Patient Visit in C - GuruFocus
Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Corbus Pharma CMO Nicacio Leonardo Viana files initial beneficial ownership statement - Bitget
Obesity Treatment Study Reaches Final Visit; Corbus Data Expected in September - Stock Titan
CRBP Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Corbus Pharmaceuticals Holdings Stock Price Forecast. Should You Buy CRBP? - StockInvest.us
Corbus Pharmaceuticals Holdings Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView
Corbus Pharmaceuticals Holdings Inc (CRBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Corbus Pharmaceuticals Holdings Inc. stock rises Thursday, still underperforms market - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals (CRBP) Gains FDA Nod for Pivotal CRB-701 - GuruFocus
Corbus Pharmaceuticals Holdings, Inc. initiates FDA-cleared registrational study for CRB-701 in oropharyngeal cancer - Traders Union
FDA clears Corbus registrational trial for head and neck cancer drug - Investing.com Nigeria
Corbus Pharmaceuticals Announces FDA Clearance to Initiate - GlobeNewswire
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer - The Manila Times
BlackRock, Inc. (CRBP) discloses 5.9% beneficial ownership in Corbus Pharmaceuticals - Stock Titan
Form 144 Corbus Pharmaceuticals Holdings For: 27 July By Investing.com - Investing.com Canada
Corbus Pharmaceuticals Holdings Inc - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
1.17%
1.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):